Get the Stockscreener App
10.65
17.81%
1.61
After Hours:
10.64
-0.010
-0.09%
Uniqure N V stock is traded at $10.65, with a volume of 9.57M.
It is up +17.81% in the last 24 hours and down -56.57% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$9.04
Open:
$9.04
24h Volume:
9.57M
Relative Volume:
3.21
Market Cap:
$663.41M
Revenue:
$16.10M
Net Income/Loss:
$-198.97M
P/E Ratio:
-3.0596
EPS:
-3.4809
Net Cash Flow:
$-183.99M
1W Performance:
-37.77%
1M Performance:
-56.57%
6M Performance:
-40.67%
1Y Performance:
-11.91%
1-Day Range:
$8.97
$11.33
1-Week Range:
$8.73
$17.28
52-Week Range:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
10.65 | 563.12M | 16.10M | -198.97M | -183.99M | -3.4809 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Nov-04-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
Kaplan Fox Encourages Investors of uniQure N.V. (QURE) to Contact the Firm Before Lead Plaintiff Deadline on April 13, 2026 - NewMediaWire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming DeadlinesQURE - PR Newswire
Holzer & Holzer, LLC Reminds QURE Investors of the April - GlobeNewswire
Holzer & Holzer, LLC Reminds QURE Investors of the April 13, 2026 Lead Plaintiff Deadline in the uniQure N.V. Securities Class Action - GlobeNewswire Inc.
UniQure's Experimental Treatment for Huntington's Disease Faces Criticism From FDA Official - marketscreener.com
uniQure's (QURE) Gene Therapy for Huntington's Disease Faces FDA Setback - GuruFocus
FinancialContentKaplan Fox Encourages Investors of uniQure N.V. (QURE) to Contact the Firm Before Lead Plaintiff Deadline on April 13, 2026 - FinancialContent
uniQure (NASDAQ:QURE) Shares Up 12%Here's Why - MarketBeat
U.S. FDA official says uniQure is likely the latest company to make a failed therapy for Huntington's patients - marketscreener.com
US-listed shares of uniQure NV rise nearly 20% - marketscreener.com
uniQure N.V. (QURE) Class Action Lawsuit Seeks Recovery for Investors; April 13, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - FinancialContent
What's Going On With uniQure Stock On Thursday?uniQure (NASDAQ:QURE) - Benzinga
UniQure (QURE) Faces FDA Hurdle for Huntington's Disease Therapy - GuruFocus
FDA Push for Fake Brain Surgery Trial Spurs Ethical Concerns - Bloomberg.com
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors - GlobeNewswire
QURE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - PR Newswire
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds uniQure N.V. Investors of ... - Bluefield Daily Telegraph
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - GlobeNewswire
The extremism of the FDA’s Marks and Prasad has come with costs - statnews.com
uniQure NV Hits Day Low of $15.51 Amid Price Pressure - Markets Mojo
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
uniQure NV Hits Day Low of $8.74 Amidst Intense Price Pressure - Markets Mojo
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit - Morningstar
uniQure NV Opens Weak with 12.86% Gap Down Amid Market Concerns - Markets Mojo
FDA official says UniQure fell short on Huntington's trial, defends new study request - Reuters
Why Did QURE Stock Almost Halve Pre-Market Today? - Stocktwits
ROSEN, A LONGSTANDING FIRM, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
uniQure Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
[144] uniQure N.V. SEC Filing - Stock Titan
uniQure (NASDAQ: QURE) RSUs vesting; insider sales of 12,378 and 34,437 - Stock Titan
Automatic tax-related share sale by uniQure (QURE) CEO Matthew Kapusta - Stock Titan
Tax-driven sale of 1,660 uniQure (QURE) shares by CMO - Stock Titan
uniQure Faces 2026 Shift to Dutch Large Company Regime, Curbing Direct Shareholder Control Over Board Appointments - The Globe and Mail
uniQure (QURE) Loses 67.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Finviz
What's Going On With uniQure Stock Wednesday? - Bitget
Berger Montague Reminds UniQure N.V. (QURE) Investors of Class Action Lawsuit Deadline - marketscreener.com
Investors who lost money on uniQure N.V.(QURE) should contact Levi & Korsinsky about pending Class ActionQURE - marketscreener.com
uniQure Faces Investor Lawsuit Over AMT-130 Trial Disclosures and Stock Drop - TipRanks
uniQure (QURE) Is Down 62.4% After AMT-130 Lawsuits Challenge Huntington’s Disclosure TimelineWhat's Changed - simplywall.st
uniQure: Worst Case Scenario Becomes Reality - Seeking Alpha
uniQure N.V. Securities Fraud Class Action Result of FDA - GlobeNewswire
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - GlobeNewswire Inc.
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
UniQure N.V. (QURE): Wells Fargo Assigns Equal-Weight Rating With Price Target of $60 - 富途牛牛
Kaplan Fox Alerts Investors of uniQure N.V. (QURE) to a Securities Class Action Deadline on April 13, 2026 - FinancialContent
uniQure (QURE) Downgraded by Wells Fargo, Price Target Slashed | - GuruFocus
UniQure Shares Drop After Wells Fargo, Mizuho Downgrades - marketscreener.com
US FDA Commissioner Enters New Territory Hinting At UniQure Decision While Defending Prasad - Citeline News & Insights
Experts: Regulatory roadblocks stalling rare disease therapies - bioworld.com
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Announces Target Price $40 - 富途牛牛
uniQure downgraded after FDA backs sham-controlled trial for Huntington’s therapy - Investing.com
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):